Skip to main content

Bioanalytical Systems Value Stock - Dividend - Research Selection

Bioanalytical Systems

ISIN: US09058M1036, WKN: 923198

Market price date: 21.05.2021
Market price: 26,39 USD




Bioanalytical Systems Fundamental data and company key figures of the share

Annual reports in USD
Key figures 29-12-2020
Cash flow
Net operating cash flow 1.290.000
Capital Expenditures -6.200.000
Free cash flow -4.910.000
Balance sheet
Total Equity 7.596.000
Liabilities & Shareholders equity 61.593.000
Income statement
Net income -4.685.000
Eps (diluted) -0,430
Diluted shares outstanding 10.851.000
Net sales/revenue 60.469.000

Fundamental ratios calculated on: 21-05-2021

Ratios
Key figures 21-05-2021
Cash flow
P/C 221,98
   
P/FC -58,32
Balance sheet
ROI-7,61
ROE12,33
Income statement
P/E-61,37
Div. Yield0,00%
P/B37,70
P/S4,74


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBASI
Market Capitalization286.357.888,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.basinc.com


Description of the company

Bioanalytical Systems, Inc. is a contract research company providing drug discovery and development services. The Company´s clients and partners include pharmaceutical, biotechnology, academic and Government organizations. It derives its revenues from sales of its research services and drug development tools. The Company has been involved in the research of drugs to treat a number of therapeutic areas. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. Its principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research, including biotechnology companies and pharmaceutical companies. It operates in two business segments: contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.basinc.com